Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. Read more here.

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 receptor agonists.

surveys show — and now a major new study has revealed a long list of benefits and some little-known risks. Glucagon-like peptide-1 receptor (GLP-1) agonists — which contain either semaglutide ...

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the ...

When the company reported VK2735's phase 2 results last year, the stock jumped 121% in one trading session. Viking gave back ...

“It’s not the panacea,” Al-Aly says, but rather a sort of side benefit of GLP-1 agonists. The researcher ... According to a KFF analysis, the list price for GLP-1 drugs can range between ...